NZ595378A - Immunology treatment for biofilms - Google Patents

Immunology treatment for biofilms

Info

Publication number
NZ595378A
NZ595378A NZ595378A NZ59537808A NZ595378A NZ 595378 A NZ595378 A NZ 595378A NZ 595378 A NZ595378 A NZ 595378A NZ 59537808 A NZ59537808 A NZ 59537808A NZ 595378 A NZ595378 A NZ 595378A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
biofilms
antigenic
seq
amino acid
Prior art date
Application number
NZ595378A
Other languages
English (en)
Inventor
Stuart Geoffrey Dashper
Paul David Veith
Ching Seng Ang
Eric Charles Reynolds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007903787A external-priority patent/AU2007903787A0/en
Application filed filed Critical
Priority to NZ605037A priority Critical patent/NZ605037A/en
Publication of NZ595378A publication Critical patent/NZ595378A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ595378A 2007-07-12 2008-07-11 Immunology treatment for biofilms NZ595378A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ605037A NZ605037A (en) 2007-07-12 2008-07-11 Immunology treatment for biofilms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903787A AU2007903787A0 (en) 2007-07-12 Immunology treatment for biofilms
PCT/AU2008/001018 WO2009006700A1 (en) 2007-07-12 2008-07-11 Immunology treatment for biofilms

Publications (1)

Publication Number Publication Date
NZ595378A true NZ595378A (en) 2013-04-26

Family

ID=40228121

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ595378A NZ595378A (en) 2007-07-12 2008-07-11 Immunology treatment for biofilms
NZ605037A NZ605037A (en) 2007-07-12 2008-07-11 Immunology treatment for biofilms
NZ582438A NZ582438A (en) 2007-07-12 2008-07-11 A composition for use in raising an immune response to p. gingivalis

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ605037A NZ605037A (en) 2007-07-12 2008-07-11 Immunology treatment for biofilms
NZ582438A NZ582438A (en) 2007-07-12 2008-07-11 A composition for use in raising an immune response to p. gingivalis

Country Status (10)

Country Link
US (2) US20100297179A1 (enExample)
EP (2) EP2604692A1 (enExample)
JP (2) JP2010532766A (enExample)
KR (1) KR20100071964A (enExample)
CN (2) CN102652831A (enExample)
AU (1) AU2008274907B2 (enExample)
CA (1) CA2693717A1 (enExample)
NZ (3) NZ595378A (enExample)
SG (1) SG182988A1 (enExample)
WO (1) WO2009006700A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
CN103357014A (zh) * 2007-07-12 2013-10-23 口腔健康澳洲私人有限公司 生物膜治疗
US8871213B2 (en) 2008-08-29 2014-10-28 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
RU2012107993A (ru) * 2009-08-02 2013-09-10 Санофи Пастер Лимитид Полипептиды porhyromonas gingivalis
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
CN105418758A (zh) * 2015-12-03 2016-03-23 沈阳惠民生物技术有限公司 一种抗牙周病抗体的制备方法及其应用
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN113005069B (zh) * 2021-01-28 2023-09-26 广东海洋大学 一种减毒鰤鱼诺卡氏菌及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition
US5475097A (en) * 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
US6017532A (en) * 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
EP0717747B1 (en) 1993-09-10 2003-06-04 The University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
US5523390A (en) * 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
EP0753577B1 (en) 1994-03-29 2002-07-24 Kyowa Hakko Kogyo Co., Ltd. Cell-surface polypeptide gene
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
AU742668B2 (en) * 1996-03-22 2002-01-10 Morehouse School Of Medicine Immunogenic compositions comprising porphyromonas gingivalis peptides and methods
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
EP2264176A1 (en) * 1997-12-10 2010-12-22 CSL Limited Porphorymonas gingivalis polypeptides and polynucleotides
AUPP083997A0 (en) * 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) * 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) * 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6576226B1 (en) * 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) 2000-11-30 2003-05-01 Burgess Nicola A. ginS
GB2381449A (en) 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
WO2004083425A1 (ja) 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
DK1660524T3 (da) * 2003-08-15 2011-05-09 Univ Florida Identifikation af porphyromonas gingivalis virulens polynukleotider til diagnose, behandling, og monitorering af periodontale sygdomme
EP1721283B1 (en) * 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
WO2006032104A1 (en) * 2004-09-23 2006-03-30 The University Of Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) * 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
CN103357014A (zh) * 2007-07-12 2013-10-23 口腔健康澳洲私人有限公司 生物膜治疗
US20110104179A1 (en) * 2009-06-19 2011-05-05 Oral Health Australia Pty Ltd Protease inhibitory peptides

Also Published As

Publication number Publication date
AU2008274907B2 (en) 2014-11-13
EP2176413A4 (en) 2012-08-01
CN102652831A (zh) 2012-09-05
US20100297179A1 (en) 2010-11-25
US20130202641A1 (en) 2013-08-08
AU2008274907A1 (en) 2009-01-15
EP2604692A1 (en) 2013-06-19
JP2014058541A (ja) 2014-04-03
EP2176413A1 (en) 2010-04-21
JP2010532766A (ja) 2010-10-14
WO2009006700A1 (en) 2009-01-15
US8911745B2 (en) 2014-12-16
CA2693717A1 (en) 2009-01-15
NZ582438A (en) 2012-03-30
CN101842486A (zh) 2010-09-22
KR20100071964A (ko) 2010-06-29
NZ605037A (en) 2014-05-30
SG182988A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
NZ595378A (en) Immunology treatment for biofilms
NZ595063A (en) Polypeptides from neisseria meningitidis
NZ612315A (en) Compositions for immunising against staphylococcus aureus
FI3501534T3 (fi) Rokotekoostumuksia, jotka käsittävät mutatoitua tekijä h:ta sitovaa proteiinia
NZ590010A (en) Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
NZ620441A (en) Pcsk9 vaccine
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
NZ701881A (en) Vaccines for hsv-2
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
BRPI0510430A (pt) composições e métodos para vacinação mucosal
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
MX2008009493A (es) Peptido novedoso y uso del mismo.
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
JP2010532766A5 (enExample)
MD20100029A (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) si vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
NZ594347A (en) Antibodies against human tweak and uses thereof
RU2013126888A (ru) ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JUL 2015 BY CPA GLOBAL

Effective date: 20130819

LAPS Patent lapsed